ALKERMES | ALKS - Selling And Administration Expenses


ALKERMES reported $264.59M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
ALKERMES USD 264.59M 77.4M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.03B 719M Mar/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Otsuka Holdings JPY 259.49B 18.81B Mar/2026
Ovoca Bio EUR 632K 2.33M Jun/2025
Pfizer USD 2.92B 1.16B Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026